Clinical Trials Directory

Trials / Completed

CompletedNCT01118078

Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor

Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Renal Tumor Project: Application of Array-Based Methods and Next Generation Sequencing to Identify Candidate Molecular Targets for High-Risk Wilms Tumors

Status
Completed
Phase
Study type
Observational
Enrollment
185 (actual)
Sponsor
Children's Oncology Group · Network
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

This research study is studying biomarkers in tissue samples from patients with high-risk Wilms tumor. Studying samples of tissue from patients with cancer in the laboratory may help doctors to learn more about changes that occur in DNA and identify biomarkers related to cancer.

Detailed description

OBJECTIVES: I. To assess genomic gains and losses in high risk renal tumors, including up to 80 favorable histology Wilms tumors that relapse (RFHWT), 50 anaplastic Wilms tumors (UHWT), 15 clear cell sarcomas of the kidney (CCSK), and 40 rhabdoid tumors (RT) using a high density genetic platform to survey for recurrent copy number variations and allelic imbalances. II. To define transcription patterns within 80 RFHWT, 50 UHWT, 15 CCSK, and 40 RT using a high throughput platform for global gene expression. III. To define DNA methylation patterns within 80 RFHWT, 50 UHWT, 15 CCSK, and 40 RT using a high throughput platform. IV. To identify genetic mutations involved in the pathogenesis of Wilms tumor, and in the development of relapse and anaplasia through the study of 80 RFHWT, 50 UHWT, 15 CCSK, and 40 RT using next generation sequencing tools. V. To facilitate the integration of the above databases and allow meaningful access by investigators through the infrastructure provided by TARGET, including its data portal and associated caBIG tool. OUTLINE: This is a multicenter study. Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression, DNA methylation, and genomic re-sequencing by array-based methods, including PCR analysis, methylation-specific reverse transcriptase-PCR (RT-PCR), and quantitative RT-PCR.

Conditions

Interventions

TypeNameDescription
GENETICDNA methylation analysisUndergo DNA methylation analysis
GENETICgene expression analysisUndergo gene expression analysis
GENETICmicroarray analysisUndergo microarray analysis
GENETICreverse transcriptase-polymerase chain reactionUndergo RT-PCR
OTHERdiagnostic laboratory biomarker analysisCorrelative studies

Timeline

Start date
2010-05-01
Primary completion
2016-05-01
First posted
2010-05-06
Last updated
2016-05-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01118078. Inclusion in this directory is not an endorsement.